Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Clin Cancer Res ; 28(24): 5290-5296, 2022 12 15.
Artigo em Inglês | MEDLINE | ID: mdl-36228149

RESUMO

PURPOSE: The treatment outcome for locally advanced or metastatic soft-tissue sarcoma (STS) remains unsatisfactory. Anlotinib had demonstrated impressive activity in the subsequent-line treatment of STS. This study investigated the combination of anlotinib and epirubicin followed by anlotinib maintenance as first-line treatment for patients with advanced STS. PATIENTS AND METHODS: This prospective, open-label, single-arm, phase II trial was conducted in Zhongshan Hospital, Fudan University. Eligible patients were ages 18 years or older and had previously untreated, pathologically confirmed, unresectable locally advanced or metastatic STS. All patients received up to six cycles of anlotinib plus epirubicin followed by anlotinib maintenance until disease progression, unacceptable toxicity, or death. The primary endpoint was the progression-free survival (PFS) rate at 6 months. The study was registered on chictr.org (identifier ChiCTR1900024928). RESULTS: From June 2019 to August 2020, 30 patients were enrolled. By December 2021, the median PFS was 11.5 months [95% confidence interval (CI): 8.6-14.4 months], while the median overall survival was not reached (95% CI: NE-NE). The objective response rate was 13.33% and the disease control rate was 80.0%. The most common adverse events (AE) included anemia (43.3%), nausea/vomiting (40.0%), fatigue (36.7%), leukopenia (30.0%), and proteinuria (10.0%), which were mainly of grade 1 or 2. The most frequent grade 3 or 4 AEs were anemia (10.0%), febrile neutropenia (33.3%), hypothyroidism (3.3%), and leukopenia (3.3%). No treatment-related death occurred. CONCLUSIONS: The combination of anlotinib and epirubicin followed by anlotinib maintenance demonstrated promising efficacy with a favorable safety profile.


Assuntos
Anemia , Leucopenia , Quinolinas , Sarcoma , Neoplasias de Tecidos Moles , Humanos , Adolescente , Epirubicina/efeitos adversos , Estudos Prospectivos , Neoplasias de Tecidos Moles/patologia , Sarcoma/tratamento farmacológico , Sarcoma/patologia , Quinolinas/efeitos adversos , Anemia/induzido quimicamente , Leucopenia/induzido quimicamente
2.
Carcinogenesis ; 43(10): 930-940, 2022 11 23.
Artigo em Inglês | MEDLINE | ID: mdl-35767307

RESUMO

Liver metastasis is a leading indicator of poor prognosis in patients with colorectal cancer (CRC). Exosomal intercellular communication has been reported to play an important role in cancer invasion and metastasis. Here, we characterized exosomal miRNAs underlying liver metastasis in CRC patients (Cohort 1, n = 30) using miRNA arrays. Exosomal miR-150 was found to be downregulated in CRC patients with liver metastases compared to those without (P = 0.025, fold change [FC] = 2.01). These results were then validated using another independent cohort of CRC patients (Cohort 2, n = 64). Patients with low expression of exosomal miR-150 had significantly shorter overall survival (OS) time (33.3 months versus 43.3 months, P = 0.002). In addition, the low expression of exosomal miR-150 was significantly correlated with advanced tumor node metastasis staging (P = 0.013), higher CA199 level (P = 0.018), and the presence of liver metastasis (P = 0.048). Multivariate analysis showed that low expression of exosomal miR-150 (P = 0.035) and liver metastasis (P < 0.001) were independent prognostic factors for overall survival. In vivo and in vitro studies showed that the viability and invasion of CRC cells were both significantly suppressed by ExomiR-150. Target-prediction assessment and dual-luciferase reporter assay indicated that FTO (the fat mass and obesity-associated gene) was a direct target for miR-150. This study first demonstrated that exosomal miR-150 may be a potential prognostic factor and treatment target for CRC.


Assuntos
Neoplasias Colorretais , Exossomos , Neoplasias Hepáticas , MicroRNAs , Humanos , Neoplasias Colorretais/genética , Neoplasias Colorretais/cirurgia , Neoplasias Colorretais/metabolismo , MicroRNAs/genética , MicroRNAs/metabolismo , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/cirurgia , Neoplasias Hepáticas/metabolismo , Prognóstico , Exossomos/metabolismo , Regulação Neoplásica da Expressão Gênica , Dioxigenase FTO Dependente de alfa-Cetoglutarato/genética
3.
Chem Biol Drug Des ; 90(5): 943-952, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28498641

RESUMO

Twenty-one novel 5-phenyl-1,3,4-oxadiazole-2-thiol (POT) substituted N-hydroxyethyl quaternary ammonium salts (6a-g, 7a-g, 8a-g) were prepared and characterized by FTIR, NMR, and elemental analysis. Compounds 6a, 6c, and 8a were confirmed by X-ray single-crystal diffraction. They display the unsurpassed antibacterial activity against Staphylococcus aureus, α-H-tococcus, Escherichia coli, P. aeruginosa, Proteus vulgaris, Canidia Albicans, especially 6g, 7g, 8g with dodecyl group. Compounds 8a-d with N,N-dihydroxyethyl and POT groups display unsurpassed antibacterial activity and non-toxicity. The structure-activity relationships indicate that POT and flexible dihydroxyethyl group in QAS are necessary for antibacterial activity and cytotoxicity. SEM and TEM images of E. coli morphologies of 8d show the antibacterial agents can adhere to membrane surfaces to inhibit bacterial growth by disrupting peptidoglycan formation and releasing bacterial cytoplasm from cell membranes.


Assuntos
Antibacterianos/farmacologia , Bactérias/efeitos dos fármacos , Oxidiazóis/farmacologia , Compostos de Amônio Quaternário/farmacologia , Antibacterianos/química , Infecções Bacterianas/tratamento farmacológico , Escherichia coli/efeitos dos fármacos , Humanos , Testes de Sensibilidade Microbiana , Modelos Moleculares , Oxidiazóis/química , Proteus vulgaris/efeitos dos fármacos , Compostos de Amônio Quaternário/química , Staphylococcus aureus/efeitos dos fármacos , Relação Estrutura-Atividade
4.
Chem Biol Drug Des ; 88(4): 534-41, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27096419

RESUMO

A series of heterocyclic α,ß-unsaturated carbonyl compounds (1a-1d, 2a-2d, 3a-3d, 4a-3d, and 5a-5d) with 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore were synthesized for the development of anticancer and multidrug resistance reverting agents. The antiproliferative activities were tested against nine human cancer cell lines. Approximately 73% of the IC50 values were below 5 µm, while 35% of these figures were submicromolar, and compounds 3a-3d with 4-trifluoro methyl in the arylidene benzene rings were the most potent, since their IC50 values are between 0.06 and 3.09 µm against all cancer cell lines employed. Meanwhile, their multidrug resistance reversal properties and cellular uptake were further examined. The data displayed that all of these compounds could reverse multidrug resistance, particularly, compounds 3a and 4a demonstrated both potent multidrug resistance reverting properties and strong antiproliferative activities, which can be taken as leading molecules for further research of dual effect agents in tumor chemotherapy.


Assuntos
Antineoplásicos/síntese química , Antineoplásicos/farmacologia , Resistência a Múltiplos Medicamentos/efeitos dos fármacos , Compostos Heterocíclicos/síntese química , Compostos Heterocíclicos/farmacologia , Antineoplásicos/química , Western Blotting , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Cumarínicos/química , Cumarínicos/farmacologia , Ensaios de Seleção de Medicamentos Antitumorais , Flavonoides/química , Flavonoides/farmacologia , Compostos Heterocíclicos/química , Humanos , Concentração Inibidora 50 , Estrutura Molecular , Reação em Cadeia da Polimerase em Tempo Real
5.
Int J Biol Macromol ; 84: 418-27, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26712700

RESUMO

Five water-soluble O-quaternary ammonium salt-chitosans (QAS-CS) bearing N-methyl-N-R-N, N-bis(2-hydroxyethyl) ammonium bromides (R=-benzyl (chloride, BNQAS-CS), -dodecyl (C12QAS-CS), -tetradecyl (C14QAS-CS), -hexadecyl (C16QAS-CS), -octadecyl (C18QAS-CS)) were prepared, respectively. They were characterized by FTIR, (1)H NMR and elemental analysis. Through chemical modification of O-quaternized chitosans, the water solubility of all QAS-CS was improved distinctly. Their antibacterial properties indicate good antibacterial abilities against gram-positive bacteria and bad against gram-negative bacteria, therein, C12QAS-CS and C14QAS-CS are the best. More importantly, their cytotoxicity was markedly lower than the corresponding QAS monomers by evaluating for AT2 cell line using CCK-8 assay. The strategy provides a facile way to design and develop new types of antibacterial chitosan materials with better water solubility, better antimicrobial ability and lower cytotoxicity for primary additive agent of self-owned intellectual band-aids.


Assuntos
Anti-Infecciosos/química , Anti-Infecciosos/farmacologia , Quitosana/química , Antibacterianos/síntese química , Antibacterianos/química , Antibacterianos/farmacologia , Anti-Infecciosos/síntese química , Antifúngicos/síntese química , Antifúngicos/química , Antifúngicos/farmacologia , Relação Dose-Resposta a Droga , Escherichia coli/efeitos dos fármacos , Espectroscopia de Ressonância Magnética , Testes de Sensibilidade Microbiana , Peso Molecular , Solubilidade , Espectroscopia de Infravermelho com Transformada de Fourier
6.
Oncol Lett ; 9(6): 2701-2705, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26137131

RESUMO

Retroperitoneal bronchogenic cysts (RBCs) are regarded as a rare type of congenital dysplasia disease that stems from the primitive foregut. Thus far, the exact pathogenesis of RBCs remains unknown. Due to an atypical clinical manifestation, RBCs are often incidentally detected and diagnosed by imaging modalities, such as computed tomography and magnetic resonance imaging. However, they are easily misdiagnosed due to their non-specific imaging features. Additionally, the most appropriate treatment strategy for an RBC is considered to be surgical resection. The present study reports the rare case of a 36-year-old female with a large RBC containing fatty fluid that was previously misdiagnosed as liposarcoma or cystic teratoma. Following a complex surgical resection, pathological findings confirmed a diagnosis of RBC. The follow-up examination showed that the patient was in good health at 16 months post-surgery, with no evidence of recurrence. Although rare, bronchogenic cysts must be considered in the differential diagnosis of retroperitoneal teratoma, and surgical resection should be pursued for symptom resolution and to establish a definitive histology.

7.
Chem Biol Drug Des ; 85(1): 91-7, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25215430

RESUMO

Five N-methyl-N-R-N,N-bis(2-hydroxyethyl) ammonium bromides (R = -benzyl (chloride, BNQAS), -dodecyl (C12QAS), -tetradecyl (C14QAS), -hexadecyl (C16QAS), -octadecyl (C18QAS)) were prepared based on N-methyldiethanolamine (MDEA) and halohydrocarbon. Five QAS were characterized by FTIR, NMR, and MS. BNQAS, C12QAS, C14QAS, and C16QAS were confirmed by X-ray single-crystal diffraction. Their antibacterial properties indicated good antibacterial abilities against E. coli, S. aureus, B. subtilis, especially C12QAS with the best antibacterial ability (100% to E. coli, 95.65% to S. aureus, and 91.41% to B. subtilis). In addition, C12QAS also displayed the best antifungal activities than BNQAS and C18QAS against Cytospora mandshurica, Botryosphaeria ribis, Physalospora piricola, and Glomerella cingulata with the ratio of full marks. The strategy provides a facile way to design and develop new types of antibacterial drugs for application in preventing the fruit rot, especially apple.


Assuntos
Anti-Infecciosos/síntese química , Anti-Infecciosos/farmacologia , Bactérias/efeitos dos fármacos , Alquilação , Anti-Infecciosos/química , Brometos/síntese química , Brometos/química , Brometos/farmacologia , Cristalografia por Raios X , Espectroscopia de Infravermelho com Transformada de Fourier
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA